GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » YS Biopharma Co Ltd (NAS:YS) » Definitions » ROC (Joel Greenblatt) %

YS Biopharma Co (YS Biopharma Co) ROC (Joel Greenblatt) % : -39.96% (As of Sep. 2023)


View and export this data going back to 2023. Start your Free Trial

What is YS Biopharma Co ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. YS Biopharma Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -39.96%.

The historical rank and industry rank for YS Biopharma Co's ROC (Joel Greenblatt) % or its related term are showing as below:

YS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -57.09   Med: -20.8   Max: -14.67
Current: -35.11

During the past 3 years, YS Biopharma Co's highest ROC (Joel Greenblatt) % was -14.67%. The lowest was -57.09%. And the median was -20.80%.

YS's ROC (Joel Greenblatt) % is ranked better than
74.62% of 1462 companies
in the Biotechnology industry
Industry Median: -329.055 vs YS: -35.11

YS Biopharma Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


YS Biopharma Co ROC (Joel Greenblatt) % Historical Data

The historical data trend for YS Biopharma Co's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

YS Biopharma Co ROC (Joel Greenblatt) % Chart

YS Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23
ROC (Joel Greenblatt) %
-57.09 -20.80 -14.67

YS Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial -31.07 -16.97 1.18 -29.98 -39.96

Competitive Comparison of YS Biopharma Co's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, YS Biopharma Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


YS Biopharma Co's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, YS Biopharma Co's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where YS Biopharma Co's ROC (Joel Greenblatt) % falls into.



YS Biopharma Co ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Mar. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(67.198 + 26.902 + 2.53) - (50.673 + 0.333 + 15.788)
=29.836

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(58.835 + 29.162 + 4.454) - (64.82 + 0.315 + 1.4210854715202E-14)
=27.316

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of YS Biopharma Co for the quarter that ended in Sep. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Sep. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2023  Q: Sep. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-43.962/( ( (84.588 + max(29.836, 0)) + (78.281 + max(27.316, 0)) )/ 2 )
=-43.962/( ( 114.424 + 105.597 )/ 2 )
=-43.962/110.0105
=-39.96 %

Note: The EBIT data used here is two times the semi-annual (Sep. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


YS Biopharma Co  (NAS:YS) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


YS Biopharma Co ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of YS Biopharma Co's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


YS Biopharma Co (YS Biopharma Co) Business Description

Traded in Other Exchanges
Address
38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminium-free lyophilized rabies vaccine that was launched in China. It has one operating segment, which is the development, production, marketing and sale of biopharmaceutical products.

YS Biopharma Co (YS Biopharma Co) Headlines

From GuruFocus